Are CSL shares worth buying after its latest deal?
AI مارکیٹ کا خلاصہ
CSL announced a major drug-development partnership with Alentis for a Claudin-1 targeted therapy in Phase II for a rare autoimmune kidney disease. The deal includes a US$355m upfront payment plus CSL funding ongoing development, with a 55/45 global profit split if commercialized. The news is incrementally constructive for pipeline optionality but introduces near-term deal cost and clinical/regulatory execution risk for CSL shares.
اثر کی سطح
● درمیانہ
متاثرہ اثاثے
NCSKCSCL2USD/USDT+2.31%
AI تجزیاتی سمجھ · NCSKCSCL2USD/USDTAI تجزیاتی سمجھ
● Neutral
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
CSL Limited has struck a major drug-development partnership with Alentis for an experimental therapy targeting Claudin-1. The candidate is currently in a Phase II trial for a rare autoimmune kidney disease.
Under the agreement, CSL will pay an upfront US$355 million and fund the costs of the subsequent development program. If the drug reaches the market, CSL will receive 55% of global profits, with Alentis taking 45%.
CSL shares were trading around A$177 on Tuesday. Based on consensus forecasts for FY27 to FY29 earnings per share of A$8.99 to A$10.08, the stock is valued at about 20 times earnings, easing to roughly 17.5 times on the same estimates.
